Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Devonian Health Group ( (TSE:GSD) ) just unveiled an update.
Devonian Health Group has appointed veteran biopharmaceutical finance executive and current board member Dennis Turpin as its new Chief Financial Officer, replacing Viktoria Krasteva, who will assist with the transition until late February, while Pierre Labbé assumes the role of Audit Committee chair; Turpin was also granted 25,000 stock options vesting immediately at an exercise price of $11.50 for a 10-year term. The company additionally corrected the exercise price on previously announced stock option grants to directors, consultants and employees to reflect market pricing rules and detailed how those options, along with their exercise prices, have been automatically adjusted following a recent 1-for-60 share consolidation, clarifying the capital structure and equity-based incentives for stakeholders.
More about Devonian Health Group
Devonian Health Group Inc. is a Quebec-based, clinical-stage pharmaceutical company focused on developing drugs for auto-immune fibroinflammatory diseases such as atopic dermatitis, radiodermatitis and ulcerative colitis, using novel therapeutic approaches to address unmet medical needs. The company also develops high-value cosmeceutical products based on its proprietary platforms and, through its subsidiary Altius Healthcare LP, commercializes licensed prescription pharmaceutical products in Canada; it operates a state-of-the-art extraction facility and is listed on the TSX Venture Exchange and quoted on the OTCQB Venture Market.
Average Trading Volume: 816
Technical Sentiment Signal: Buy
Current Market Cap: C$31.81M
See more data about GSD stock on TipRanks’ Stock Analysis page.